Introduction: Relevant studies have demonstrated that glucocorticoids and antihistamines, such as budesonide and azelastine, are effective in the treatment of vasomotor rhinitis, with their combined use being more effective than that of a single drug. The aim of this study was to assess the improvement in the symptoms of patients following the combined administration of these drugs. Methods: We conducted a single-center randomized study on 42 patients. Participants were randomly treated with budesonide, levocabastine hydrochloride, or their combination for 2 weeks. The visual analog scale (VAS) score and levels of eosinophil cationic protein (ECP), histamine (HA), leukotriene B4 (LTB4), and vasoactive intestinal peptide (VIP) in nasal secretions were evaluated before and after treatment. Results: The symptoms of patients were improved in all 3 treatment groups compared with those before treatment. Following combined treatment, the improvement in symptoms of nasal obstruction, runny nose, nasal itching, and sneezing was much greater than those in the groups treated with budesonide or levocabastine hydrochloride alone (p = 0.04, 0.004, 0.005, 0.004, respectively). The decreased levels of these inflammatory mediators were significantly different between the different treatment groups. Conclusions: Budesonide or levocabastine hydrochloride alone improved the nasal symptoms of patients with vasomotor rhinitis and reduced the levels of ECP, HA, LTB4, and VIP in nasal secretions. However, their combination improved the symptoms of patients more significantly than each drug alone.

1.
Kaliner
MA
.
Classification of nonallergic rhinitis syndromes with a focus on vasomotor rhinitis, proposed to be known henceforth as nonallergic rhinopathy
.
World Allergy Organ J
.
2009
;
2
(
6
):
98
101
.
2.
Nathan
RA
,
Meltzer
EO
,
Derebery
J
,
Campbell
UB
,
Stang
PE
,
Corrao
MA
.
The prevalence of nasal symptoms attributed to allergies in the United States: findings from the burden of rhinitis in an America survey
.
Allergy Asthma Proc
.
2008
;
29
(
6
):
600
8
.
3.
Scarupa
MD
,
Kaliner
MA
.
Nonallergic rhinitis, with a focus on vasomotor rhinitis clinical importance, differential diagnosis, and effective treatment recommendations
.
World Allergy Organ J
.
2009
;
2
(
3
):
20
5
.
4.
Settipane
RA
.
Epidemiology of vasomotor rhinitis
.
World Allergy Organ J
.
2009
;
2
(
6
):
115
8
.
5.
Singh
U
,
Bernstein
JA
,
Lorentz
H
,
Sadoway
T
,
Nelson
V
,
Patel
P
.
A pilot study investigating clinical responses and biological pathways of azelastine/fluticasone in nonallergic vasomotor rhinitis before and after cold dry air provocation
.
Int Arc Allergy Immunol
.
2017
;
173
(
3
):
153
164
.
6.
Banov
CH
,
Lieberman
P
Vasomotor Rhinitis Study Groups
.
Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis
.
Ann Allergy Asthma Immunol
.
2001
;
86
(
1
):
28
35
.
7.
Shusterman
D
,
Murphy
MA
.
Nasal hyperreactivity in allergic and non-allergic rhinitis: a potential risk factor for non-specific building-related illness
.
Indoor Air
.
2007
;
17
(
4
):
328
33
.
8.
Nassef
M
,
Shapiro
G
,
Casale
TB
Respiratory and Allergic Disease Foundation
.
Identifying and managing rhinitis and its subtypes: allergic and nonallergic components: a consensus report and materials from the Respiratory and Allergic Disease Foundation
.
Curr Med Res Opin
.
2006
;
22
(
12
):
2541
8
.
9.
Gelardi
M
,
Maselli Del Giudice
A
,
Fiorella
ML
,
Soleti
P
,
Di Gioacchino
M
,
Conti
CM
.
Quality of life in non-allergic rhinitis depends on the predominant inflammatory cell type
.
J Biol Regul Homeost Agents
.
2008
;
22
(
1
):
73
81
.
10.
Bernstein
JA
.
Nonallergic rhinitis: therapeutic options
.
Curr Opin Allergy Clin Immunol
.
2013
;
13
(
4
):
410
6
.
11.
Papon
JF
,
Brugel-Ribere
L
,
Fodil
R
,
Croce
C
,
Larger
C
,
Rugina
M
.
Nasal wall compliance in vasomotor rhinitis
.
J Appl Physiol
.
2006
;
100
(
1
):
107
11
.
12.
Horak
F
,
Zieglmayer
UP
.
Azelastine nasal spray for the treatment of allergic and nonallergic rhinitis
.
Expert Rev Clin Immunol
.
2009
;
5
(
6
):
659
69
.
13.
Lange
B
,
Lukat
KF
,
Rettig
K
,
Holtappels
G
,
Bachert
C
.
Efficacy, cost-effectiveness, and tolerability of mometasone furoate, levocabastine, and disodium cromoglycate nasal sprays in the treatment of seasonal allergic rhinitis
.
Ann Allergy Asthma Immunol
.
2005
;
95
(
3
):
272
82
.
14.
Pipkorn
U
,
Berge
T
.
Long-term treatment with budesonide in vasomotor rhinitis
.
Acta Otolaryngol
.
1983
95
1–2
167
71
.
15.
Lal
D
,
Corey
JP
.
Vasomotor rhinitis update
.
Curr Opin Otolaryngol Head Neck Surg
.
2004
;
12
(
3
):
243
7
.
16.
Song
K
,
Gong
ZP
,
Ma
YF
,
Chen
Y
.
Therapeutic effect of nasal corticosteroids combined with nasal antihistamine on vasomotor rhinitis
.
J Clin Otorhinol, Head Neck Surg
.
2018
;
32
(
23
):
1783
7
.
17.
Chen
H
,
Zhang
L
,
Lou
H
,
Wang
Y
,
Cao
F
,
Wang
C
.
A randomized trial of comparing a combination of montelukast and budesonide with budesonide in allergic rhinitis
.
Laryngoscope
.
2021 Apr
131
4
E1054
61
.
18.
Meng
Y
,
Wang
Y
,
Lou
H
,
Wang
K
,
Meng
N
,
Zhang
L
.
Specific immunoglobulin E in nasal secretions for the diagnosis of local allergic rhinitis
.
Rhin
.
2019
;
0
(
0
):
0
20
.
19.
Ma
Y
,
Tan
G
,
Zhao
Z
,
Li
W
,
Huang
L
,
Liu
G
.
Therapeutic effectiveness of endoscopic vidian neurectomy for the treatment of vasomotor rhinitis
.
Acta Otolaryngol
.
2014
;
134
(
3
):
260
7
.
20.
Anggård
A
.
Vasomotor rhinitis--pathophysiological aspects
.
Rhinology
.
1979
;
17
(
1
):
31
5
.
You do not currently have access to this content.